Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Summary

This is a multi-site, randomized, prospective, open-label phase II study. Patients in this study will have localized (cT3-cT4), or metastatic bladder cancer with a symptomatic, intact primary bladder tumor. In this study, patients will undergo stereotactic body radiation therapy (SBRT) to the bladder tumor and will receive durvalumab with or without tremelimumab.

Timeline

Start

2017-10-01

Primary completion

2021-09-01

Completion

2024-09-01

Outcome

Outcome not reported

Stopped: “Co-PI Albert Chang relocating to UCLA. IND will transfer to UCLA. UCSF will not participate.”

Drugs

Indications